Search

Your search keyword '"Richou, Carine"' showing total 150 results
Start Over Author "Richou, Carine"
150 results on '"Richou, Carine"'

1. Association between the dietary inflammatory index and the risk of hepatocellular carcinoma in a cirrhotic population

Author

Di Martino, V., Doffoel, M., Thieffin, G., Binquet, C., Petit, Jm, Minello, A., Latournerie, M., Sgro, C., Trechot, P., Valnet-Rabier, Mb, Trenque, T., Tebacher-Alt, M., Faivre, J., Masson, D., Delmas, D., Duvillard, L., Guéant, Jl, Jooste, V., Manfait, M., Oudet, P., Sockalingum, G., Vuitton, D., Rizk, Maud, Roux-Levy, Cécile, Bernard-Chabert, Brigitte, Bronowicki, Jean-Pierre, Richou, Carine, Habersetzer, François, Jouve, Jean-Louis, Hebert, James R., Shivappa, Nitin, Boutron-Ruault, Marie-Christine, Diab Assaf, Mona, Hillon, Patrick, and Cottet, Vanessa

Published
2025
Full Text
View/download PDF

5. Alveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts

Author

Marquis Bastian, Demonmerot Florent, Richou Carine, Thiéfin Gérard, Millon Laurence, Wallon Martine, Vuitton Dominique Angèle, Grall-Jezequel Anne, Grenouillet Frédéric, Epaulard Olivier, Gervais Philippe, Manuel Oriol, and Bresson-Hadni Solange

Subjects
solid-organ transplant, alveolar echinococcosis, echinococcus multilocularis, immunosuppression, Infectious and parasitic diseases, RC109-216
Abstract

Alveolar echinococcosis (AE) is a severe parasitic infection caused by the ingestion of Echinococcus multilocularis eggs. While higher incidence and faster evolution have been reported in immunosuppressed patients, no studies have been performed specifically on AE in transplant patients. We searched for all de novo AE cases diagnosed between January 2008 and August 2018 in solid organ transplant (SOT) recipients included in the Swiss Transplant Cohort Study and the FrancEchino Registry. Eight cases were identified (kidney = 5, lung = 2, heart = 1, liver = 0), half of which were asymptomatic at diagnosis. AE diagnosis was difficult due to the low sensitivity (60%) of the standard screening serology (Em2+) and the frequently atypical radiological presentations. Conversely, Echinococcus Western blot retained good diagnostic performances and was positive in all eight cases. Five patients underwent surgery, but complete resection could only be achieved in one case. Moreover, two patients died of peri-operative complications. Albendazole was initiated in seven patients and was well tolerated. Overall, AE regressed in one, stabilized in three, and progressed in one case, and had an overall mortality of 37.5% (3/8 patients). Our data suggest that AE has a higher mortality and a faster clinical course in SOT recipients; they also suggest that the parasitic disease might be due to the reactivation of latent microscopic liver lesions through immune suppression. Western blot serology should be preferred in this population. Finally, surgery should be considered with caution, because of its low success rate and high mortality, and conservative treatment with albendazole is well tolerated.

Published
2023
Full Text
View/download PDF

6. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère

Published
2019
Full Text
View/download PDF

8. Circulating cell-free DNA in patients with alveolar echinococcosis

Author

Felix, Sophie, Heyd, Bruno, Mantion, Georges, Di Martino, Vincent, Montange, Damien, Vanlemmens, Claire, Vuitton, Dominique Angèle, Weil-Verhoeven, Delphine, Chavanet, Pascal, Dalle, Frédéric, Gohier, Sandrine, Minello, Anne, Piroth, Lionel, Dumortier, Jérôme, Mabrut, Jean-Yves, Wallon, Martine, Frentiu, Emilia, Machouart, Marie, Watelet, Jérôme, Chemla, Cathy, Feron, Thomas, Heurge-Berlot, Alexandra, Sommacale, Daniele, Thiefin, Gerard, Abou-Bacar, Ahmed, Brunet, Julie, Candolfi, Ermano, Hansmann, Yves, Lefebvre, Nicolas, Baraquin, Alice, Hervouet, Eric, Richou, Carine, Flori, Pierre, Peixoto, Paul, Azizi, Amel, Delabrousse, Eric, Blagosklonov, Oleg, Umhang, Gerald, Bresson-Hadni, Solange, Valot, Benoit, and Grenouillet, Frédéric

Published
2018
Full Text
View/download PDF

9. Molecular diagnosis of alveolar echinococcosis in patients based on frozen and formalin-fixed paraffin-embedded tissue samples

Author

Knapp Jenny, Lallemand Séverine, Monnien Franck, Felix Sophie, Valmary-Degano Séverine, Courquet Sandra, Demonmerot Florent, Heyd Bruno, Turco Celia, Doussot Alexandre, Bourgeois Lucie, Bresson-Hadni Solange, Richou Carine, and Millon Laurence

Subjects
echinococcus multilocularis, molecular diagnosis, fresh material, ffpe, end-point pcr, qpcr, Infectious and parasitic diseases, RC109-216
Abstract

Confirmed diagnosis of alveolar echinococcosis (AE) is based on pathological criteria and molecular evidence. This parasite-borne disease, caused by the cestode Echinococcus multilocularis, sparingly involves humans as a dead-end host. In humans, the parasite mainly colonizes the liver but can colonize any organ and cause atypical forms, often difficult to characterize clinically. Moreover, molecular methods may be suitable to make the diagnosis of AE in cases of atypical forms, extra-hepatic localizations, or immunosuppressed patients. The aim of this study was to determine the most relevant published PCR techniques, for diagnosis of AE in patients and adopt the best strategy for molecular diagnosis depending on the nature of the tested sample. In this study, we evaluated nine end-point PCR assays and one real-time PCR assay (qPCR), targeting mitochondrial genes, using a total of 89 frozen or formalin-fixed paraffin-embedded (FFPE) samples from either 48 AE or 9 cystic echinococcosis patients. Targeted fragment-genes ranged from 84 to 529 bp. Six PCR assays were able to amplify the DNA of 100% of the frozen AE-samples and for one PCR, 69.8% of the FFPE AE-samples. The 16S rrnL PCR (84 bp) was positive in PCR for 77% of the AE samples and in qPCR for 86.5%. The sensitivity of the PCR assays was higher for fresh samples and FFPE samples stored for less than 5 years. The qPCR assay further increased sensitivity for the tested samples, confirming the need for the development of an Echinococcus spp. qPCR to improve the molecular diagnosis of echinococcoses.

Published
2022
Full Text
View/download PDF

10. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study

Author

Faivre, Morgan, Cottet, Vanessa, Bour, Jean-Baptiste, Richou, Carine, Valmary-Degano, Séverine, Thiefin, Gerard, Andreoletti, Laurent, Geist, Claire, Schvoerer, Evelyne, Malvé, Brice, Habersetzer, François, Fafi-Kremer, Samira, Binquet, Christine, Jouve, Jean-Louis, Bronowicki, Jean-Pierre, Doffoel, Michel, Hillon, Patrick, Herbein, Georges, Monnet, Elisabeth, and Di Martino, Vincent

Published
2018
Full Text
View/download PDF

11. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

Author

Merle, Philippe, primary, Bouattour, Mohamed, additional, Blanc, Jean-Frédéric, additional, Peron, Jean-Marie, additional, Debette-Gratien, Marilyne, additional, Nahon, Pierre, additional, Nguyen-Khac, Eric, additional, Phelip, Jean Marc, additional, Assenat, Eric, additional, Bourgeois, Vincent, additional, Richou, Carine, additional, Heurgue, Alexandra, additional, Bronowicki, Jean-Pierre, additional, Ollivier-Hourmand, Isabelle, additional, Uguen, Thomas, additional, Cattan, Stéphane, additional, Thevenon, Sylvie, additional, Boucheny, Camille, additional, and Pradat, Pierre, additional

Published
2023
Full Text
View/download PDF

12. Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis

Author

Weil, Delphine, Levesque, Eric, McPhail, Marc, Cavallazzi, Rodrigo, Theocharidou, Eleni, Cholongitas, Evangelos, Galbois, Arnaud, Pan, Heng Chih, Karvellas, Constantine J., Sauneuf, Bertrand, Robert, René, Fichet, Jérome, Piton, Gaël, Thevenot, Thierry, Capellier, Gilles, Di Martino, Vincent, Di Martino, Vincent, Weil, Delphine, Thévenot, Thierry, Cervoni, Jean-Paul, Richou, Carine, Vanlemmens, Claire, Dritsas, Stavros, Capellier, Gilles, Piton, Gaël, Chaignat, Claire, Pili-Floury, Sébastien, Blasco, Gilles, Samain, Emmanuel, Samuel, Didier, Levesque, Eric, Saliba, Faouzi, Ichaï, Philippe, Galbois, Arnaud, Guidet, Bertrand, Das, Vincent, Sauneuf, Bertrand, Mira, Jean-Paul, Perrotin, Dominique, Champigneulle, Benoit, Pene, Frédéric, Robert, René, Filloux, Bruno, Silvain, Christine, Fichet, Jérome, McPhail, Marc, Wendon, Julia, Shawcross, Debbie, Bernal, William, Theocharidou, Eleni, Agarwal, Banwari, Burroughs†, Andrew K., Cholongitas, Evangelos, Cavallazzi, Rodrigo, Karvellas, Constantine J., Pan, Heng Chih, Chen, Yung-Chang, Tsai, Ming-Hung, and METAREACIR Group

Published
2017
Full Text
View/download PDF

14. Diagnostic de l’échinococcose alvéolaire

Author

Bresson-Hadni, Solange, Grenouillet, Frédéric, Chauchet, Adrien, Richou, Carine, Knapp, Jenny, Delabrousse, Éric, Adrian-Félix, Sophie, Blagosklonov, Oleg, Vuitton, Dominique-Angèle, and Millon, Laurence

Published
2014
Full Text
View/download PDF

16. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study

Author

Thévenot, Thierry, primary, Vendeville, Sophie, additional, Weil, Delphine, additional, Akkouche, Linda, additional, Calame, Paul, additional, Canivet, Clémence M., additional, Vanlemmens, Claire, additional, Richou, Carine, additional, Cervoni, Jean-Paul, additional, Seronde, Marie-France, additional, Di Martino, Vincent, additional, and Boursier, Jérôme, additional

Published
2022
Full Text
View/download PDF

21. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients

Author

Mouillot, Thomas, Rizk, Maud, Pais de Barros, Jean-Paul, Gilloteau, Adrien, Busson, Amandine, Bernard-Chabert, Brigitte, Thiefin, Gérard, Barraud, Hélène, Bronowicki, Jean-Pierre, Richou, Carine, Di Martino, Vincent, Doffoel, Michel, Minello, Anne, Latournerie, Marianne, Jouve, Jean-Louis, Brondel, Laurent, Brindisi, Marie-Claude, Petit, Jean-Michel, Hillon, Patrick, Cottet, Vanessa, Group, for the CiRCE Study, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Strasbourg, Centre National de la Recherche Scientifique (CNRS), CHU Metz, UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), Cancéropôle du Grand-Est (CGE), Ligue Nationale contre le Cancer, Fondation de France, Canceropole Grand-Est, European Regional Development Fund, Agence Nationale de la Recherche, Institut National du Cancer, Conseil Régional de Bourgogne-Franche-Comté, and ANR-11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011)

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Endogeny, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Odds Ratio, medicine, Carcinoma, Humans, Pharmacology (medical), Phospholipids, Aged, 030304 developmental biology, chemistry.chemical_classification, 0303 health sciences, Hepatology, business.industry, Erythrocyte Membrane, Fatty Acids, Liver Neoplasms, Case-control study, Fatty acid, Odds ratio, Metabolism, Middle Aged, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, digestive system diseases, 3. Good health, chemistry, Case-Control Studies, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers
Abstract

International audience; BACKGROUND: Disturbances in fatty acid (FA) metabolism have been reported in cirrhosis, but the role of FAs in the development of hepatocellular carcinoma (HCC) is still unclear. Biomarkers are a promising means to explore the associations between exogenous intake or endogenous production of FAs and cancer risk. AIMS: To estimate the relationship between fatty acid content in erythrocyte membranes and HCC risk in cirrhotic patients. METHODS: The "CiRCE" case-control study recruited cirrhotic patients from six French hospitals between 2008 and 2012. Cases were cirrhotic patients with HCC (n = 349); controls were cirrhotic patients without HCC at inclusion (n = 550). FA composition of phospholipids in erythrocyte membranes was determined by high performance gas chromatography. Odds ratios for HCC risk according to FA concentrations were estimated with multivariable logistic regression. RESULTS: HCC patients were older and more often men (P

Published
2020
Full Text
View/download PDF

22. Investigating new serological and tissue markers for the follow‐up of patients operated for alveolar echinococcosis

Author

Bellanger, Anne‐Pauline, primary, Wang, Junhua, additional, Gbaguidi‐Haore, Houssein, additional, Barrera, Coralie, additional, Bresson‐Hadni, Solange, additional, Zlobec, Inti, additional, Lachenmayer, Anja, additional, Richou, Carine, additional, Turco, Celia, additional, Gottstein, Bruno, additional, Millon, Laurence, additional, and Beldi, Guido, additional

Published
2021
Full Text
View/download PDF

28. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis

Author

Faivre, Morgan, Cottet, Vanessa, Bour, Jean-Baptiste, Richou, Carine, Valmary-Degano, Séverine, Thiefin, Gerard, Andreoletti, Laurent, Geist, Claire, Schvoerer, Evelyne, Malve, Brice, Habersetzer, François, Fafi-Kremer, Samira, Binquet, Christine, Jouve, Jean-Louis, Bronowicki, Jean-Pierre, Doffoël, Michel, Hillon, Patrick, Herbein, Georges, Monnet, Elisabeth, Di Martino, Vincent, Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'hépatogastroentérologie (CHU Reims), Centre Hospitalier Universitaire de Reims (CHU Reims), Unité de virologie médicale [Reims], Hôpital Robert Debré, Service d'Hépato-gastro-entérologie [CHR Metz-Thionville], Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Service d'Hépato-gastro-entérologie [CHRU Nancy], Service d’Hépatogastroentérologie, NHC, CHU de Strasbourg, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Service d'Anatomie pathologique [CHRU Besançon]

Subjects
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Clinical aspects, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cirrhosis and its complications, digestive system diseases, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Goals: The aims of this study were to evaluate whether cytomegalovirus (CMV) infection is associated with hepatocellular carcinoma (HCC) and liver-related mortality in cirrhotic patients.Background: In cirrhotic patients, the determinants of HCC and liver-related death are imperfectly known. CMV infection, by its prooncogenic and proinflammatory properties, may favor both the development of HCC and deleterious systemic inflammation.Study: In the 1178 patients included between June 2008 and December 2012 in the CIrrhose et Risque de Carcinome Hépatocellulaire dans le grand-Est (CIRCE) study, a French multicenter case-control study designed to identify risk factors of HCC among cirrhotic patients, we identified 432 patients with interpretable CMV serological status at baseline. They included 159 cases with HCC and 273 controls. We measured factors associated with HCC at baseline and subsequent HCC in controls, and predictors of overall and liver-related death in the whole study population.Results: During a median follow-up of 31 months, 25 cases of HCC developed in controls, and 209 deaths (163 liver-related) were recorded. There were 247 (57.2%) CMV-seropositive patients. CMV seropositivity was not associated with more frequent HCC at baseline or during follow-up, but among CMV-positive patients with HCC, the proportion of multinodular, infiltrative, or metastatic tumors at diagnosis was higher (73.8% vs. 57.3%; P=0.029), inducing higher mortality (74% vs. 52% at 3 years; P=0.004). By Cox-regression adjusted for age, gender, Model for End-stage Liver Disease (MELD) score, HCC at baseline, and diabetes, CMV seropositivity independently predicted all-cause (hazard ratio=1.45; 95% confidence interval, 1.08-1.94; P=0.013) and liver-related mortality (hazard ratio=1.56; 95% confidence interval, 1.04-2.30; P=0.031).Conclusions: In this preliminary study, CMV-seropositive cirrhotic patients were at higher risk of liver-related death caused by more aggressive HCCs or severe cirrhosis complications. These findings warrant confirmation.

Published
2019
Full Text
View/download PDF

29. Comparison of the serological tests ICT and ELISA for the diagnosis of alveolar echinococcosis in France☆

Author

Knapp Jenny, Sako Yasuhito, Grenouillet Frédéric, Bresson-Hadni Solange, Richou Carine, Gbaguidi-Haore Houssein, Ito Akira, and Millon Laurence

Subjects
alveolar echinococcosis, diagnosis, rEm18, immunochromatography, rapid test, rEm18-ELISA and Em2-Em18-ELISA tests, Infectious and parasitic diseases, RC109-216
Abstract

Serological diagnosis of alveolar echinococcosis (AE) is a key element for efficient patient treatment management. A rapid immunochromatography test kit (ICT) using the recombinant Em18 antigen (rEm18) was recently developed. The aim of our study was to assess this test on a panel of sera from French patients with alveolar echinococcosis and control patients. In a blind test, a total of 112 serum samples were tested including samples of AE (n = 30), cystic echinococcosis [CE] (n = 15), and polycystic echinococcosis [PE] (n = 1). For the comparison, 66 sera from patients with hepatocarcinoma, fascioliasis, toxocariasis, Caroli’s disease, or autoimmune chronic active hepatitis were used. The diagnostic test sets we used were the rEm18-ICT and two validated ELISAs with rEm18 and Em2-Em18 antigens, respectively. For the ICT, 27/30 sera from AE patients, 4/15 sera from CE patients and the PE patient serum were positive. One serum from the control panel (toxocariasis) was positive for the ICT. The rEm18-ICT sensitivity (90.0%) and specificity (92.7%) for detection of Em18-specific antibodies confirmed it as a relevant tool for AE diagnosis. The rEm18-ELISA had a sensitivity of 86.7% and specificity of 91.5%, and the Em2-Em18-ELISA had a sensitivity of 96.7% and specificity of 87.8%. However, when AE patient sera are recorded as weak in intensity with the ICT, we recommend a double reading and use of a reference sample if the ICT is used for patient follow-up.

Published
2014
Full Text
View/download PDF

30. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, RELIVE Investigators, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, and RELIVE Investigators

Abstract

BACKGROUND: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. METHODS: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT01655693. FINDINGS: Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 397 were randomly assigned to one of the groups (133 to the 30 mg/m2 group; 130 to the 20 mg/m2 group; and 134 to the control group). Median follow-up was 22·7 months (IQR 11·2-34·9). After pooling the doxorubicin groups for the efficacy analysis, median overall survival was 9·1 months (95% CI 8·1-10·4) in the pooled doxorubicin-loaded nanoparticles group and 9·0 months (7·1-11·8) in the control group (HR 1·00 [95% CI 0·78-1·28], two-sided p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 tr

Published
2019

31. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Merle, Philippe, primary, Blanc, Jean-Frederic, additional, Phelip, Jean-Marc, additional, Pelletier, Gilles, additional, Bronowicki, Jean-Pierre, additional, Touchefeu, Yann, additional, Pageaux, Georges, additional, Gerolami, René, additional, Habersetzer, François, additional, Nguyen-Khac, Eric, additional, Casadei-Gardini, Andrea, additional, Borbath, Ivan, additional, Tran, Albert, additional, Wege, Henning, additional, Saad, Amr Shafik, additional, Colombo, Massimo, additional, Abergel, Armand, additional, Richou, Carine, additional, Waked, Imam, additional, Yee, Nelson S, additional, Molé, Audrey, additional, Attali, Pierre, additional, Le Boulicaut, Julie, additional, Vasseur, Bérangère, additional, Moussata, Driffa, additional, Grangé, Jean-Didier, additional, Ratziu, Vlad, additional, Khemissa-Akouz, Faiza, additional, Regnault, Hélène, additional, Dauvois, Barbara, additional, Zarski, Jean-Pierre, additional, Ollivier-Hourmand, Isabelle, additional, Manfredi, Sylvain, additional, Debette-Gratien, Marilyne, additional, Gangloff, Alice, additional, Fontanges, Thierry, additional, Baron, Aurore, additional, Bouattour, Mohamed, additional, Vincent, Julie, additional, Sieghart, Wolfgang, additional, Maieron, Andreas, additional, Peeters, Marc, additional, Delwaide, Jean, additional, Lasser, Luc, additional, Berg, Thomas, additional, Schultheiß, Michael, additional, Zipprich, Alexander, additional, Trojan, Joerg, additional, Ehmer, Ursula, additional, Luppi, Gabriele, additional, Luca, Giovanni, additional, Tamberi, Stefano, additional, Amoroso, Domenico, additional, Alabiso, Oscar, additional, Buonadonna, Angela, additional, Toniutto, Pierluigi, additional, Tamburini, Emiliano, additional, Cubillo, Antonio, additional, Muñoz, Andrés, additional, Guillén, Carmen, additional, Sánchez, Gloria, additional, Manzano, Hermini, additional, Navarro, Victor, additional, Ales, Inmaculada, additional, Massuti, Bartomeu, additional, Dank, Magdolna, additional, Bodoky, György, additional, Kahan, Zsuzsanna, additional, Horváth, Zsolt, additional, Gabrail, Nashat, additional, Ozer, Howard, additional, Galanopoulos, Christos, additional, Hauke, Ralph, additional, Raj, Moses, additional, Harputluoglu, Hakan, additional, Sevinc, Alper, additional, Goker, Erdem, additional, Coker, Ahmet, additional, Yalcin, Suayib, additional, Ali, Muhammet, additional, Ata, Ozlem, additional, Tugba, Ilkay, additional, El Kassas, Mohammed, additional, Abdel, Amr, additional, Wakid, Imam, additional, Shamaa, Sameh, additional, El Lahlouby, Nasr, additional, Kohail, Hanaa, additional, Makarem, Jawad, additional, Chehade, Issam, additional, Farhat, Fadi, additional, López, Carlos, additional, and Marín, Miguel, additional

Published
2019
Full Text
View/download PDF

33. Préservation de la fertilité dans un contexte d'échinococcose alvéolaire avec atteinte ovarienne bilatérale : à propos d'un cas.

Author

Decaigny, Pauline, Metz, Jean-Patrick, Berdin, Aurélie, Lenoir, Marion, Millon, Laurence, Richou, Carine, and Ramanah, Rajeev

Abstract

Copyright of Médecine de la Reproduction is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020
Full Text
View/download PDF

34. Circulating cell-free DNA in patients with alveolar echinococcosis

Author

Baraquin, Alice, primary, Hervouet, Eric, additional, Richou, Carine, additional, Flori, Pierre, additional, Peixoto, Paul, additional, Azizi, Amel, additional, Delabrousse, Eric, additional, Blagosklonov, Oleg, additional, Umhang, Gerald, additional, Bresson-Hadni, Solange, additional, Valot, Benoit, additional, Grenouillet, Frédéric, additional, Felix, Sophie, additional, Heyd, Bruno, additional, Mantion, Georges, additional, Di Martino, Vincent, additional, Montange, Damien, additional, Vanlemmens, Claire, additional, Vuitton, Dominique Angèle, additional, Weil-Verhoeven, Delphine, additional, Chavanet, Pascal, additional, Dalle, Frédéric, additional, Gohier, Sandrine, additional, Minello, Anne, additional, Piroth, Lionel, additional, Dumortier, Jérôme, additional, Mabrut, Jean-Yves, additional, Wallon, Martine, additional, Frentiu, Emilia, additional, Machouart, Marie, additional, Watelet, Jérôme, additional, Chemla, Cathy, additional, Feron, Thomas, additional, Heurge-Berlot, Alexandra, additional, Sommacale, Daniele, additional, Thiefin, Gerard, additional, Abou-Bacar, Ahmed, additional, Brunet, Julie, additional, Candolfi, Ermano, additional, Hansmann, Yves, additional, and Lefebvre, Nicolas, additional

Published
2018
Full Text
View/download PDF

35. Prognostic Impact of 3-HM Concentration in Patients with Alcoholic or Viral Cirrhosis

Author

Granconato, Laura, primary, Barros, Jean-Paul Pais de, additional, Mouillot, Thomas, additional, Lagrost, Laurent, additional, Bernard-Chabert, Brigitte, additional, Thiefin, Gerard, additional, Louis Jouve, Jean, additional, Bronowicki, Jean Pierre, additional, Richou, Carine, additional, Di Martino, Vincent, additional, Doffoel, Michel, additional, Binquet, Christine, additional, Petit, Jean Michel, additional, Minello, Anne, additional, Latournerie, Marianne, additional, Cottet, Vanessa, additional, Hillon, Patrick, additional, and Group, CIRCE Study, additional

Published
2018
Full Text
View/download PDF

36. Doxorubicin-Loaded Nanoparticles for Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib: RELIVE, a Phase-3 Trial

Author

Merle, Philippe, primary, Blanc, Jean-Frederic, additional, Phelip, Jean-Marc, additional, Pelletier, Gilles, additional, Bronowicki, Jean Pierre, additional, Touchefeu, Yann, additional, Pageaux, Georges, additional, Gerolami, René, additional, Habersetzer, François, additional, Nguyen Khac, Eric, additional, Casadei Gardini, Andrea, additional, Borbath, Ivan, additional, Tran, Albert, additional, Wege, Henning, additional, Shafik Saad, Amr, additional, Colombo, Massimo, additional, Abergel, Armand, additional, Richou, Carine, additional, Waked, Imam, additional, Yee, Nelson, additional, Molé, Audrey, additional, Attali, Pierre, additional, Le Boulicaut, Julie, additional, Vasseur, Bérangère, additional, and Investigators, RELIVE, additional

Published
2018
Full Text
View/download PDF

37. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease

Author

Oussalah, Abderrahim, Avogbe, Patrice Hodonou, Guyot, Erwan, Chery, Céline, Guéant, Rosa-Maria, Ganne-Carrié, Nathalie, Cobat, Aurélie, Moradpour, Darius, Nalpas, Bertrand, Negro, Francesco, Poynard, Thierry, Pol, Stanislas, Bochud, Pierre, Abel, Laurent, Jeulin, Hélène, Schvoerer, Evelyne, Chabi, Nicodème, Amouzou, Emile, Sanni, Ambaliou, Barraud, Hélène, Rouyer, Pierre, Josse, Thomas, Goffinet, Laetitia, Jouve, Jean-Louis, Minello, Anne, Bonithon-Kopp, Claire, Thiefin, Gérard, Di Martino, Vincent, Doffoël, Michel, Richou, Carine, Raab, Jean-Jacques, Hillon, Patrick, Bronowicki, Jean-Pierre, Guéant, Jean-Louis, Nutrition-Génétique et Exposition aux Risques Environnementaux ( NGERE ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lorraine ( UL ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Université Paris 13 ( UP13 ), Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP), Génomique Fonctionnelle des Tumeurs Solides ( U1162 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Lausanne ( UNIL ), Département d'hépatologie [CHU Cochin], Institut Pasteur [Paris]-CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'Hydrogéologie et de Géothermie [Neuchâtel] ( CHYN ), Université de Neuchâtel ( UNINE ), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Sorbonne Université, Service d'hépatologie médicale [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), The Rockefeller University [New-York], Université de Lorraine ( UL ), Laboratoire de Virologie [Strasbourg], Université de Kara, University of Abomey Calavi ( UAC ), Service d'Hépato-gastro-entérologie [CHRU Nancy], Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Service d'hépatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), CHU Strasbourg, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre hospitalier régional Metz-Thionville ( CHR Metz-Thionville ), This study was supported by a French Government grant managed by the French National Research Agency under the program 'Investissements d’Avenir', reference ANR-11-LABX-0021 and also by the Institut National du Cancer (INCA), the French regions of Lorraine and Burgundy, the Ligue Nationale contre le Cancer (CiRCE-Nutrigenex), the European Regional Development Fund, the Canceropole Grand-Est, and the Fondation de France.The ANRS Study HC EP 26 Genoscan group is supported by the National Agency for Research on AIDS and Viral Hepatitis (ANRS).The Swiss Hepatitis C Cohort Study (SCCS) is supported by grants from the Swiss National Science Foundation (3347C0-108782/1), the Swiss Federal Office for Education and Sciences (03.0599) and the European Commission (LSHM-CT-2004-503359, VIRGIL Network of Excellence on Antiviral Drug Resistance). The SCCS genetic project is supported by the Leenaards foundation, the Santos-Suarez foundation and the Swiss National Science Foundation (324730-144054), ANR-11-LABX-0021/11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du ( 2011 ), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université Paris 13 (UP13), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lausanne (UNIL), CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Hydrogéologie et de Géothermie [Neuchâtel] (CHYN), Université de Neuchâtel (UNINE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Rockefeller University [New York], Université de Lorraine (UL), Service de Virologie [CHRU Nancy], Stress, Immunité, Pathogènes (SIMPA), University of Abomey Calavi (UAC), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), ANR-11-LABX-0021/11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011), CiRCE Study Group, Hôpital Jean Verdier, Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Département d'hépathologie [CHU Cochin], Université de Neuchâtel, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université d'Abomey Calavi, Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], Laboratoire de Chimie Physique et Microbiologie pour l'Environnement (LCPME), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and ANR-11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011)

Subjects
hepatitis C virus, BRIP1, DNA repair genes, hepatitis B virus, hepatocellular carcinoma, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human genetics, Research Paper, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

IF 5.008; International audience; The molecular mechanisms of hepatocellular carcinoma (HCC) carcinogenesis are still not fully understood. DNA repair defects may influence HCC risk. The aim of the study was to look for potential genetic variants of DNA repair genes associated with HCC risk among patients with alcohol- or viral-induced liver disease. We performed four case-control studies on 2,006 European- (Derivation#1 and #2 studies) and African-ancestry (Validation#1 and #2 studies) patients originating from several cohorts in order to assess the association between genetic variants on DNA repair genes and HCC risk using a custom array encompassing 94 genes. In the Derivation#1 study, the BRIP1 locus reached array-wide significance (Chi-squared SV-Perm, P=5.00×10-4) among the 253 haplotype blocks tested for their association with HCC risk, in patients with viral cirrhosis but not among those with alcoholic cirrhosis. The BRIP1 haplotype block included three exonic variants (rs4986763, rs4986764, rs4986765). The BRIP1 'AAA' haplotype was significantly associated with an increased HCC risk [odds ratio (OR), 2.01 (1.19-3.39); false discovery rate (FDR)-P=1.31×10-2]. In the Derivation#2 study, results were confirmed for the BRIP1 'GGG' haplotype [OR, 0.53 (0.36-0.79); FDR-P=3.90×10-3]. In both Validation#1 and #2 studies, BRIP1 'AAA' haplotype was significantly associated with an increased risk of HCC [OR, 1.71 (1.09-2.68); FDR-P=7.30×10-2; and OR, 6.45 (4.17-9.99); FDR-P=2.33×10-19, respectively]. Association between the BRIP1 locus and HCC risk suggests that impaired DNA mismatch repair might play a role in liver carcinogenesis, among patients with HCV- or HBV-related liver disease.

Published
2016
Full Text
View/download PDF

38. Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients

Author

Valot, Benoît, primary, Rognon, Bénédicte, additional, Prenel, Anais, additional, Baraquin, Alice, additional, Knapp, Jenny, additional, Anelli, Mathilde, additional, Richou, Carine, additional, Bresson‐Hadni, Solange, additional, Grenouillet, Frederic, additional, Wang, Junhua, additional, Vuitton, Dominique Angèle, additional, Gottstein, Bruno, additional, and Millon, Laurence, additional

Published
2017
Full Text
View/download PDF

40. Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions

Author

Sondag Daniel, Cusenier Bernadette, Alby-Lepresle Blandine, Delattre Jean Francois, Gerard Alain, Samuel Didier, Farges Olivier, Dominique A. Vuitton, Letranchant Lorraine, Jenny Knapp, Watelet Jérôme, Brientini Marie Pascale, Bresson-Hadni Solange, Guillaud Olivier, Hillon Patrick, Cappelle Sylvie, Piarroux Martine, Debruyne Monique, Vuitton Dominique Angèle, Valmary-Degano Séverine, Godet Claire, Adrien Chauchet, Beytout Jean, Hansmann Yves, Laurence Millon, Besancenot Jean François, Li Véronique, Contreras Remy, Raoul Francis, Vitrat Virginie, Eric Delabrousse, Partensky Christian, Koch Stéphane, Mantion Georges, Evrard Philippe, Delabrousse Eric, Carine Richou, Dumortier Jérôme, Raabe Jean-Jacques, Remy Contreras, Wallon Martine, Beurton-Chataigner Isabelle, Abou-Bacar Ahmed, Di Martino Vincent, Chemla Cathy, Heyd Bruno, Machouart Marie, Audet Maxime, Richou Carine, Oleg Blagosklonov, Vanlemmens Claire, Minello Anne, Bardonnet Karine, Giraudoux Patrick, Felix Sophie, Frédéric Grenouillet, Blagosklonov Oleg, Abergel Armand, Vuitton Lucine, Rabodonirina Meja, Faure Odile, Charlotte Dentan, Guerin Bruno, Grenouillet Frédéric, Knapp Jenny, Lefebvre Nicolas, Johann Marc, Solange Bresson-Hadni, Cambon Monique, Chatelain Eric, Eric Deconinck, Letoublon Christian, Prost Patricia, Bartholomot Brigitte, Vincent Di Martino, Millon Laurence, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté (UFC), Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Microbiology (medical), Echinococcosis, Hepatic, medicine.medical_specialty, Delayed Diagnosis, medicine.medical_treatment, Echinococcus multilocularis, Risk Assessment, Gastroenterology, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, Albendazole, Serology, Immunocompromised Host, Echinococcosis, Risk Factors, Internal medicine, medicine, Humans, Abscess, Aged, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, biology, business.industry, Incidence, Incidence (epidemiology), Immunosuppression, Middle Aged, medicine.disease, biology.organism_classification, 3. Good health, Surgery, Infectious Diseases, Concomitant, Female, business, Liver abscess, medicine.drug
Abstract

International audience; BACKGROUND: An increased incidence of alveolar echinococcosis (AE) in patients with immunosuppression (IS) has been observed; our aim was to study this association and its characteristics. METHODS: Fifty AE cases with IS-associated conditions (ISCs) before or at AE diagnosis were collected from the French AE registry (1982-2012, 509 cases). There were 30 cancers, 9 malignant hematological disorders, 14 chronic inflammatory diseases, 5 transplants, and 1 case of AIDS; 9 patients had ≥2 ISCs. Characteristics of the 42 IS/AE cases and the 187 non-IS/AE cases diagnosed during the period 2002-2012 were statistically compared. RESULTS: There was a significant increase in IS/AE cases over time. Risk factors did not differ between IS/AE and non-IS/AE patients. However, AE was more frequently an incidental finding (78% vs 42%) and was diagnosed at earlier stages (41% vs 23%) in IS/AE than in non-IS/AE patients. Serology was more often negative (14% vs 1%) and treatment efficacy was better (51% regression after 1-year treatment vs 27%) in IS/AE patients. All IS/AE patients but 7 took IS drugs; 7 received biotherapeutic agents. When not concomitant, AE occurred in IS patients within a 48-month median time period. Atypical presentation and abscess-, hemangioma-, and metastasis-like images delayed AE diagnosis in 50% of IS/AE patients, resulting in inappropriate treatment. Liver images obtained for 15 patients 1-5 years before diagnosis showed no AE lesions. Albendazole efficacy was good, but 19 of 48 treated patients experienced side effects. CONCLUSIONS: Patients with immunosuppression are at increased risk for occurrence, delayed diagnosis, and progression of AE.

Published
2014
Full Text
View/download PDF

41. Hints for control of infection in unique extrahepatic vertebral alveolar echinococcosis

Author

Faucher, Jean-François, primary, Descotes-Genon, Cécile, additional, Hoen, Bruno, additional, Godard, Joël, additional, Félix, Sophie, additional, Aubry, Sébastien, additional, Blagosklonov, Oleg, additional, Grenouillet, Frédéric, additional, Brientini, Marie-Pascale, additional, Richou, Carine, additional, Bresson-Hadni, Solange, additional, and Chirouze, Catherine, additional

Published
2016
Full Text
View/download PDF

43. L’échinococcose alvéolaire humaine en France en 2010 / Box – Human alveolarechinococcosis in France, update 2010

Author

Grenouillet, Frédéric, Knapp, J., Millon, Laurence, Raton, Vincent, Richou, Carine, Piarroux, Martine, Piarroux, Renaud, Mantion, Georges André, Vuitton, D.A., Bresson-Hadni, Solange, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), Entente de lutte interdépartementale contre les zoonoses ( ELIZ ), Etablissement Public Interdépartemental, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de la Méditerranée - Aix-Marseille 2, WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Entente de Lutte Interdépartementale contre les Zoonoses (ELIZ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Franche-Comté (UFC), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Entente de lutte interdépartementale contre les zoonoses (ELIZ), and Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)

Subjects
[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, ComputingMilieux_MISCELLANEOUS, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health
Abstract

International audience

Published
2010

44. Em+ Elisa: a serological test able to predict long term outcome in inoperable alveolar echinococcosis patients under benzimidazole therapy

Author

Richou, Carine, Grenouillet, Frédéric, Delabrousse, Eric, Blagosklonov, Oleg, Ma, Shu Mei, Millon, Laurence, Mantion, Georges André, Di Martino, Vincent, Bresson-Hadni, Solange, WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté ( UFC ), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, and Agents pathogènes et inflammation - UFC (EA 4266) ( API )

Subjects
[ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, ComputingMilieux_MISCELLANEOUS, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology
Abstract

International audience

Published
2009

45. Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions

Author

Chauchet, Adrien, primary, Grenouillet, Frédéric, additional, Knapp, Jenny, additional, Richou, Carine, additional, Delabrousse, Eric, additional, Dentan, Charlotte, additional, Millon, Laurence, additional, Di Martino, Vincent, additional, Contreras, Remy, additional, Deconinck, Eric, additional, Blagosklonov, Oleg, additional, Vuitton, Dominique A., additional, Bresson-Hadni, Solange, additional, Virginie, Vitrat, additional, Karine, Bardonnet, additional, Brigitte, Bartholomot, additional, Isabelle, Beurton-Chataigner, additional, Oleg, Blagosklonov, additional, Solange, Bresson-Hadni, additional, Pascale, Brientini Marie, additional, Sylvie, Cappelle, additional, Remy, Contreras, additional, Eric, Delabrousse, additional, Vincent, Di Martino, additional, Philippe, Evrard, additional, Sophie, Felix, additional, Patrick, Giraudoux, additional, Frédéric, Grenouillet, additional, Bruno, Heyd, additional, Séverine, Valmary-Degano, additional, Jenny, Knapp, additional, Stéphane, Koch, additional, Georges, Mantion, additional, Laurence, Millon, additional, Francis, Raoul, additional, Carine, Richou, additional, Claire, Vanlemmens, additional, Angèle, Vuitton Dominique, additional, Lucine, Vuitton, additional, Patricia, Prost, additional, Claire, Godet, additional, Armand, Abergel, additional, Jean, Beytout, additional, Monique, Cambon, additional, François, Besancenot Jean, additional, Bernadette, Cusenier, additional, Patrick, Hillon, additional, Anne, Minello, additional, Odile, Faure, additional, Christian, Letoublon, additional, Jérôme, Dumortier, additional, Olivier, Guillaud, additional, Christian, Partensky, additional, Meja, Rabodonirina, additional, Martine, Wallon, additional, Martine, Piarroux, additional, Eric, Chatelain, additional, Marc, Johann, additional, Jean-Jacques, Raabe, additional, Daniel, Sondag, additional, Alain, Gerard, additional, Lorraine, Letranchant, additional, Marie, Machouart, additional, Jérôme, Watelet, additional, Olivier, Farges, additional, Didier, Samuel, additional, Cathy, Chemla, additional, Francois, Delattre Jean, additional, Bruno, Guerin, additional, Monique, Debruyne, additional, Ahmed, Abou-Bacar, additional, Maxime, Audet, additional, Yves, Hansmann, additional, Nicolas, Lefebvre, additional, Véronique, Li, additional, and Blandine, Alby-Lepresle, additional

Published
2014
Full Text
View/download PDF

46. Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis

Author

Petit, Jean Michel, primary, Hamza, Samia, additional, Rollot, Fabien, additional, Sigonney, Vanessa, additional, Crevisy, Elodie, additional, Duvillard, Laurence, additional, Raab, Jean Jacques, additional, Bronowicki, Jean Pierre, additional, Bernard-Chabert, Brigitte, additional, Di Martino, Vincent, additional, Doffoel, Michel, additional, Barraud, Helene, additional, Richou, Carine, additional, Jouve, Jean Louis, additional, and Hillon, Patrick, additional

Published
2013
Full Text
View/download PDF

47. Detecting nested clusters of human alveolar echinococcosis

Author

SAID-ALI, ZEINABA, primary, GRENOUILLET, FRÉDÉRIC, additional, KNAPP, JENNY, additional, BRESSON-HADNI, SOLANGE, additional, VUITTON, DOMINIQUE ANGÈLE, additional, RAOUL, FRANCIS, additional, RICHOU, CARINE, additional, MILLON, LAURENCE, additional, and GIRAUDOUX, PATRICK, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results